Market Cap | 272.91M | P/E | - | EPS this Y | 38.30% | Ern Qtrly Grth | - |
Income | -78.9M | Forward P/E | -2.43 | EPS next Y | 18.00% | 50D Avg Chg | -23.00% |
Sales | 6.31M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -26.00% |
Dividend | N/A | Price/Book | 2.22 | EPS next 5Y | - | 52W High Chg | -59.00% |
Recommedations | 1.70 | Quick Ratio | 1.83 | Shares Outstanding | 55.16M | 52W Low Chg | 28.00% |
Insider Own | 1.62% | ROA | -25.37% | Shares Float | 21.33M | Beta | 1.86 |
Inst Own | 93.95% | ROE | -129.15% | Shares Shorted/Prior | 5.62M/5.61M | Price | 4.96 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 174,832 | Target Price | 11.14 |
Oper. Margin | -776.95% | Earnings Date | Aug 6 | Volume | 93,236 | Change | -5.52% |
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
HC Wainwright & Co. | Buy | Aug 15, 24 |
Wedbush | Outperform | Aug 7, 24 |
Chardan Capital | Buy | Aug 7, 24 |
Raymond James | Outperform | Jun 18, 24 |
HC Wainwright & Co. | Buy | May 13, 24 |
Chardan Capital | Buy | May 7, 24 |
HC Wainwright & Co. | Buy | Apr 30, 24 |
Piper Sandler | Overweight | Apr 3, 24 |
Chardan Capital | Buy | Apr 1, 24 |